You are here: Industry Insights > Venetoclax

News List

ASCO: Combo Regimen Effective in CLL With Coexisting Conditions drugs
June 05, 2019
Combo Regimen Effective in CLL With Coexisting Conditions.
Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL drugs
May 31, 2019
Ibrutinib, Venetoclax Active in High-Risk, Seniors With CLL.
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients drugs
May 22, 2019
AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients.
FDA Approves Venetoclax for CLL and SLL americanpharmaceuticalreview
May 17, 2019
The Food and Drug Administration (FDA) has approved venetoclax (VENCLEXTA, AbbVie and Genentech) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA Approves Venetoclax for Chronic, Small Lymphocytic Leukemia drugs
May 17, 2019
FDA Approves Venetoclax for Chronic, Small Lymphocytic Leukemia.
91 percent response rate for venetoclax against newly diagnosed AML in older adults worldpharmanews
November 30, 2018
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML).
Roche’s Venclexta filed in the US for acute myeloid leukemia pharmatimes
July 13, 2018
Roche group Genentech has filed an application to market Venclexta in the US for acute myeloid leukemia (AML).
NEJM publishes venetoclax/rituximab data pharmatimes
March 23, 2018
The combination of venetoclax and rituximab developed by AbbVie and Roche/Genentech significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL).

Previous page 1 2 Next page